These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26230629)

  • 1. Risk of radiation-induced secondary rectal and bladder cancer following radiotherapy of prostate cancer.
    Stokkevåg CH; Engeseth GM; Hysing LB; Ytre-Hauge KS; Ekanger C; Muren LP
    Acta Oncol; 2015; 54(9):1317-25. PubMed ID: 26230629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of inter-fractional anatomy variation on secondary cancer risk estimates following radiotherapy.
    Stokkevåg CH; Engeseth GM; Hysing LB; Ytre-Hauge KS; Muren LP
    Phys Med; 2017 Oct; 42():271-276. PubMed ID: 28941739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling of organ-specific radiation-induced secondary cancer risks following particle therapy.
    Stokkevåg CH; Fukahori M; Nomiya T; Matsufuji N; Engeseth GM; Hysing LB; Ytre-Hauge KS; Rørvik E; Szostak A; Muren LP
    Radiother Oncol; 2016 Aug; 120(2):300-6. PubMed ID: 27424291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer.
    Murray L; Mason J; Henry AM; Hoskin P; Siebert FA; Venselaar J; Bownes P;
    Radiother Oncol; 2016 Aug; 120(2):293-9. PubMed ID: 27370205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of radiogenic second cancers following volumetric modulated arc therapy and proton arc therapy for prostate cancer.
    Rechner LA; Howell RM; Zhang R; Etzel C; Lee AK; Newhauser WD
    Phys Med Biol; 2012 Nov; 57(21):7117-32. PubMed ID: 23051714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pelvic Lymph Node Irradiation Including Pararectal Sentinel Nodes for Prostate Cancer Patients: Treatment Optimization Comparing Intensity Modulated X-rays, Volumetric Modulated Arc Therapy, and Intensity Modulated Proton Therapy.
    Vees H; Dipasquale G; Nouet P; Zilli T; Cozzi L; Miralbell R
    Technol Cancer Res Treat; 2015 Apr; 14(2):181-9. PubMed ID: 24694113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk for second bladder and rectal malignancies from cervical cancer irradiation.
    Mazonakis M; Lyraraki E; Tolia M; Damilakis J
    J Appl Clin Med Phys; 2021 Jul; 22(7):103-109. PubMed ID: 34021692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary bladder and rectal cancer risk estimates following standard fractionated and moderately hypofractionated VMAT for prostate carcinoma.
    Mazonakis M; Kachris S; Damilakis J
    Med Phys; 2020 Jul; 47(7):2805-2813. PubMed ID: 32266979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of second cancers according to radiation therapy technique and modality in prostate cancer survivors.
    Berrington de Gonzalez A; Wong J; Kleinerman R; Kim C; Morton L; Bekelman JE
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):295-302. PubMed ID: 25636756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of secondary cancer risk after radiotherapy in high-risk prostate cancer patients with pelvic irradiation.
    Haciislamoglu E; Gungor G; Aydin G; Canyilmaz E; Guler OC; Zengin AY; Yenice KM
    J Appl Clin Med Phys; 2020 Sep; 21(9):82-89. PubMed ID: 32671989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma.
    Brodin NP; Munck Af Rosenschöld P; Aznar MC; Kiil-Berthelsen A; Vogelius IR; Nilsson P; Lannering B; Björk-Eriksson T
    Acta Oncol; 2011 Aug; 50(6):806-16. PubMed ID: 21767178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of dose escalation on secondary cancer risk after radiotherapy of prostate cancer.
    Schneider U; Lomax A; Besserer J; Pemler P; Lombriser N; Kaser-Hotz B
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):892-7. PubMed ID: 17459608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of IMRT and proton radiotherapy on secondary cancer incidence.
    Schneider U; Lomax A; Pemler P; Besserer J; Ross D; Lombriser N; Kaser-Hotz B
    Strahlenther Onkol; 2006 Nov; 182(11):647-52. PubMed ID: 17072522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of 6 and 15 MV on intensity-modulated radiation therapy prostate cancer treatment: plan evaluation, tumour control probability and normal tissue complication probability analysis, and the theoretical risk of secondary induced malignancies.
    Hussein M; Aldridge S; Guerrero Urbano T; Nisbet A
    Br J Radiol; 2012 Apr; 85(1012):423-32. PubMed ID: 22010028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
    Nieder AM; Porter MP; Soloway MS
    J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second cancers in children treated with modern radiotherapy techniques.
    Schneider U; Lomax A; Timmermann B
    Radiother Oncol; 2008 Nov; 89(2):135-40. PubMed ID: 18707783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy.
    Myrehaug S; Chan G; Craig T; Weinberg V; Cheng C; Roach M; Cheung P; Sahgal A
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e657-62. PubMed ID: 22245189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies.
    Krasnow RE; Rodríguez D; Nagle RT; Mossanen M; Kibel AS; Chang SL
    Urol Oncol; 2018 Nov; 36(11):500.e11-500.e19. PubMed ID: 30249519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy.
    Georg D; Hopfgartner J; Gòra J; Kuess P; Kragl G; Berger D; Hegazy N; Goldner G; Georg P
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):715-22. PubMed ID: 24521685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the feasibility of volumetric-modulated arc therapy using simultaneous integrated boost (SIB-VMAT): An analysis for complex head-neck, high-risk prostate and rectal cancer cases.
    Cilla S; Deodato F; Digesù C; Macchia G; Picardi V; Ferro M; Sallustio G; De Spirito M; Piermattei A; Morganti AG
    Med Dosim; 2014; 39(1):108-16. PubMed ID: 24342167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.